A Phase 1A/1B Trial Of Ly3962673 In Participants With Kras G12d-Mutant Solid Tumors
Posted Date: Mar 10, 2025
- Investigator: Davendra Sohal
- Type of Study: Drug
The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Criteria:
Inclusion Criteria: Have Histological Or Cytologically Proven Diagnosis Of Locally Advanced, Unresectable, And/Or Metastatic Cancer And Measurable Disease Per Response Evaluation Criteria In Solid Tumors (Recist) Version 1.1. Have Evidence Of Kras G12d Mutation In Tumor Tissue Or Circulating Tumor Dna Have An Ecog Performance Status Of = 1 Must Have Received = 1 Prior Line Of Systemic Chemotherapy For Advanced Or Metastatic Disease Participants With Asymptomatic Or Treated Cns Disease May Be Eligible. Exclusion Criteria: Have Known Active Cns Metastases And/Or Carcinomatous Meningitis. Have Any Unresolved Toxicities From Prior Therapy Greater Than National Cancer Institute (Nci) Common Terminology Criteria For Adverse Events (Ctcae) V5.0 Grade 1. Have Significant Cardiovascular Disease As Unstable Angina Or Acute Coronary Syndrome, History Of Myocardial Infarction, Known Reduced Left Ventricular Ejection Fraction. Have Active Uncontrolled Systemic Bacterial, Viral, Fungal, Or Parasitic Infection. Have Known Active Hepatitis B Virus (Hbv) And Hepatitis C Virus (Hcv). Have Other Active Malignancy Unless In Remission With Life Expectancy Greater Than (>) 2 Years.
Keywords:
Kras G12d, Ly3962673, Carcinoma
For More Information:
Kayla Webb
NULL
cancer@uchealth.com